Pfizer and GSK to Initiate Study of Novel Combination Therapy in Patients with Melanoma

  Pfizer and GSK to Initiate Study of Novel Combination Therapy in Patients
  with Melanoma

     Phase I/II Study combines GSK’s trametinib and Pfizer’s palbociclib

Business Wire

NEW YORK -- November 21, 2013

Pfizer Inc. announced today that it has entered into an agreement with GSK to
explore the anti-cancer efficacy and the safety of GSK’s trametinib
(GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II
study (Study 200344) in patients with advanced/metastatic melanoma.

Study 200344 is a dose-escalation, open-label study designed to determine the
recommended combination regimen (RCR) for trametinib plus palbociclib in
patients with melanoma. The study will also evaluate the effect of the
combination on tumor biomarkers, safety and anti-cancer activity in patients
with BRAFV600 wild type melanoma, including those with NRAS mutations.

“Pfizer Oncology is committed to maximizing the value of our portfolio for
patients through the study of novel combinations. This includes combining our
own cancer medicines with each other, as well as with those of other companies
where there is strong scientific rationale,” said Garry Nicholson, president
and general manager, Pfizer Oncology Business Unit. “Emerging data suggest the
potential for trametinib and palbociclib to work together to treat melanoma.
We look forward to collaborating with GSK to explore this potential and
evaluate the clinical activity of this combination in melanoma.”

The two companies will collaborate on the study, which GSK will conduct.
Financial terms of the agreement were not disclosed.

Trametinib, a reversible inhibitor of MEK1 and MEK2, is approved by the U.S.
Food and Drug Administration (FDA) under the name Mekinist® for the treatment
of adult patients with unresectable or metastatic melanoma with BRAF V600E or
V600K mutation as detected by an FDA-approved test. Mekinist is not indicated
for the treatment of patients who have received a prior BRAF inhibitor

Palbociclib is an investigational oral and selective inhibitor of cyclin
dependent kinases (CDK) 4 and 6. In April 2013, palbociclib received
Breakthrough Therapy designation by the FDA for the potential treatment of
patients with breast cancer. Palbociclib is not approved for any indication in
any markets.

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development
of innovative treatment options to improve the outlook for cancer patients
worldwide. Our strong pipeline of biologics and small molecules, one of the
most robust in the industry, is studied with precise focus on identifying and
translating the best scientific breakthroughs into clinical application for
patients across a wide range of cancers. By working collaboratively with
academic institutions, individual researchers, cooperative research groups,
governments, and licensing partners, Pfizer Oncology strives to cure or
control cancer with breakthrough medicines, to deliver the right drug for each
patient at the right time. For more information, please visit

DISCLOSURE NOTICE: The information contained in this release is as of November
21, 2013. Pfizer assumes no obligation to update forward-looking statements
contained in this release as the result of new information or future events or

This release contains forward-looking information about an investigational
combination therapy of trametinib and palbociclib for the potential treatment
of melanoma, including its potential benefits, that involves substantial risks
and uncertainties. Such risks and uncertainties include, among other things:

  *the uncertainties inherent in research and development including, without
    limitation, the ability to meet anticipated clinical trial commencement
    and completion dates, as well as the possibility of unfavorable clinical
    trial results;
  *whether and when any applications may be filed with regulatory authorities
    in various jurisdictions for the combination therapy for the treatment of
    melanoma, and whether and when regulatory authorities may approve any such
    applications, as well as their decisions regarding labeling and other
    matters that could affect its availability or commercial potential; and
  *competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s
Annual Report on Form 10-K/A for the fiscal year ended December 31, 2012 and
in its reports on Form 10-Q and Form 8-K.


Pfizer Inc.
Katherine Reuter, 212-733-3416
Suzanne Harnett, 212-733-8009
Press spacebar to pause and continue. Press esc to stop.